BFBIO · BF Biosciences Limited
Transmission of Annual Financial Statements for the Year Ended 30-06-2026
- Filed
- 7 October 2026 at 2:09 pm
- Category
- Financials
- Sentiment
- Good
- Impact
- High
AI executive summary
BF Biosciences Limited reported strong financial results for the year ended June 30, 2026, with net revenue surging 62% year-on-year to PKR 9,461.25 million and profit after tax increasing 41% to PKR 632.13 million. The Board of Directors decided not to recommend any cash dividend for the year due to ongoing expansion and investment requirements.
Key takeaways
- Net revenue for FY 2026 reached PKR 9,461,254 thousand, representing a 62% increase compared to PKR 5,837,466 thousand in FY 2025.
- Gross profit improved to PKR 4,087,705 thousand from PKR 2,287,831 thousand, with the gross profit margin expanding to 43% from 39%.
- Profit before tax stood at PKR 1,067,407 thousand compared to PKR 723,738 thousand in the prior year.
- Profit after tax grew by 41% YoY to PKR 632,127 thousand, translating to basic earnings per share (EPS) of PKR 7.16 compared to PKR 5.52 last year.
- The Board of Directors decided not to recommend any cash dividend for the year ended June 30, 2026, in order to retain cash flows to support expansion plans.
Filing details
Financial results
Annual · Audited · Standalone · 30 June 2026
Figures in Rupees in thousands
Reporting period
Year
- Income
- 9,461,254 (prior 5,837,466)
- Profit after tax
- 632,127 (prior 447,147)
- EPS
- 7.16 (prior 5.52)
- The Board of Directors decided not to recommend any cash dividend for the year ended 30 June 2026 to retain cashflows for expansion plans.
- The Board recommended the reappointment of M/s KPMG Taseer Hadi & Co., Chartered Accountants as auditors for the year 2026-27.
Dividend and entitlement
- Type
- None
- Notes
- Transmission of annual financial statements with no declared dividend or corporate action.
- #bfbio
- #annual_results
- #financial_statements
- #pharmaceuticals
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.